Restless legs syndrome - the under-recognised non-motor burden: a questionnaire-based cohort study

Sauerbier, Anna; Sivakumar, Chaamanti; Klingelhoefer, Lisa; Martinez‐Martín, Pablo; Perkins, Lauren; Inniss, Rona; Rizos, Alexandra; Trivedi, Dhaval; Leta, Valentina; Wan, Yi Min; Parry, Miriam; Wamelen, Daniel J. van; Reichmann, Heinz

doi:10.1080/00325481.2019.1658506

Cited by 8 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, stress has been shown to have a major impact on neurodegeneration affecting behavioral symptoms in brain disorders such as Parkinson's disease (PD) [3,4]. There is considerable evidence to show that most individuals with PD also display anxiety, depression, or cognitive deficits many years before their diagnosis of PD [5][6][7][8][9]. It is well known that exposure to stress during early life can have long-term detrimental effects on brain development [1].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson’s Disease

Dallé

Daniels

Mabandla

2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Nonmotor symptoms (NMS) such as anxiety, depression, and cognitive deficits are frequently observed in Parkinson’s disease (PD) and precede the onset of motor symptoms by years. We have recently explored the short-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) on dopaminergic neurons in a parkinsonian rat model. Here, we report the long-term effects of Fluvoxamine, on early-life stress-induced changes in the brain and behavior. We specifically evaluated the effects of Fluvoxamine on brain mechanisms that contribute to NMS associated with PD in a unilateral 6-hydroxydopamine-lesioned rat model. A 14-day early postnatal maternal separation protocol was applied to model early-life stress followed by unilateral intracerebral infusion of 6-hydroxydopamine (6-OHDA) to model aspects of parkinsonism in rats. The anxiolytic, antidepressant, and cognitive effects of Fluvoxamine were confirmed using the elevated plus-maze (EPM) test, sucrose preference test (SPT), and Morris water maze (MWM) test. Further to that, our results showed that animals exposed to early-life stress displayed increased plasma corticosterone and malondialdehyde (MDA) levels which were attenuated by Fluvoxamine treatment. A 6-OHDA lesion effect was evidenced by impairment in the limb-use asymmetry test as well as decreased dopamine (DA) and serotonin levels in the striatum, prefrontal cortex, and hippocampus. These effects were surprisingly attenuated by Fluvoxamine treatment in all treated rats. This study is the first to suggest that early and long-term treatment of neuropsychological diseases with Fluvoxamine may decrease the vulnerability of dopaminergic neurons that degenerate in the course of PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson’s Disease

Dallé

Daniels

Mabandla

2020

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…All the 74 patients with idiopathic RLS included in the study conducted by Sauerbier et al reported at least two NMS, the most-reported being insomnia, followed by nocturia and sad feelings [ 57 ]. In one longitudinal study including 109 PwPD assessed also with NMSQ, the non-motor symptoms that were prone to be correlated with RLS were insomnia (at RLS diagnosis), dizziness and daytime sleepiness (at follow-up), in comparison with PwPD − RLS [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Restless Legs Syndrome in Parkinson’s Disease

Diaconu

Irincu

Ungureanu

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Restless legs syndrome (RLS) might worsen sleep quality and quality of life in people with Parkinson’s disease (PwPD). Objective: The main aim of the present study is to explore the associations between RLS and sleep, quality of life and other non-motor symptoms (NMS) in a sample of PwPD. Methods: We compared the clinical features of 131 PwPD with and without RLS, in a cross-sectional study. We used several validated scales for assessment: the International Restless Legs Syndrome Study Group rating scale (IRLS), Parkinson’s Disease Sleep Scale version 2 (PDSS-2), Parkinson’s Disease Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQ) and International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS). Results: Thirty-five patients (26.71%) out of the total PwPD met the RLS diagnostic criteria, without significant differences between male (57.14%) and female (42.87%) (p = 0.431). Higher total scores of PDSS-2 were recorded among PwPD + RLS (p < 0.001), suggesting worse sleep quality. Significant correlations were observed between the diagnosis of RLS and some types of pain (especially nocturnal pain), physical fatigue and probable sleep-disordered breathing, according to the MDS-NMSS assessment. Conclusions: RLS has a high frequency in PwPD and it requires proper management, considering its consequences on sleep and quality of life.

show abstract

Tagesschläfrigkeit bei Patienten mit unbehandeltem Restless-Legs-Syndrom

Eich,

Ottersbach,

Geisler

et al. 2024

Somnologie

View full text Add to dashboard Cite

Background Restless legs syndrome (RLS), a disorder characterized by an urge to move one’s legs during sleep or rest, leads to impaired sleep quality. Many patients with RLS report increased daytime sleepiness, but this has seldom been the focus of clinical research. The current study empirically investigated the prevalence and severity of daytime sleepiness in RLS. Methods This prospective study included 29 newly diagnosed treatment-naïve patients with RLS and 31 healthy controls and assessed standardized subjective (tiredness symptom scale [TSS], Stanford Sleepiness Scale [SSS], Epworth Sleepiness Scale [ESS]), cognitive (psychomotor vigilance task [PVT], Mackworth Clock Test [MCT]), and physiological measures (pupillary unrest index [PUI]). RLS symptom severity was assessed, and the effects of RLS on general health aspects and subjective sleep quality (Pittsburgh Sleep Quality Index) were compared to control data. Results Patients had moderate to severe RLS with significant negative effects on general health, quality of life, and sleep quality. Patients with RLS showed more subjective daytime sleepiness (ESS) and current sleepiness (TSS, SSS) than controls. The objective performance of patients in sustained attention tasks (P VT, MCT) was significantly worse than that of controls. Additionally, patients showed higher PUI scores. Conclusion In the present study, RLS was associated with markedly impaired subjective sleep quality and with subjectively and objectively increased daytime sleepiness. Since daytime sleepiness can be a major factor leading to compromised quality of life, assessing and treating sleepiness should be incorporated into standard diagnostics and treatment.

show abstract

Restless legs syndrome - the under-recognised non-motor burden: a questionnaire-based cohort study

Cited by 8 publications

References 48 publications

Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson’s Disease

Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson’s Disease

Restless Legs Syndrome in Parkinson’s Disease

Tagesschläfrigkeit bei Patienten mit unbehandeltem Restless-Legs-Syndrom

Contact Info

Product

Resources

About